Answers are grounded in this paper and cite their sources.
Starting in 2020, we quantified anti-wildtype SARS-CoV-2 spike sera IgG at monthly intervals from generally healthy adults after various doses of mRNA-based COVID-19 vaccination and in the context of hybrid immunity. Confirmed post-vaccination infections and subclinical infections identified by longitudinal serology were removed from vaccine-only analyses. Over 400 days, the two-dose vaccine-alone antibody response decayed at a half-life ( t 1/2 ) of 59.8 days compared with a t 1/2 of 99.7 days after receipt of one booster dose. In the hybrid immunity model, the t 1/2 was greater at 241 days. Using cut-offs for correlation of protection obtained in a prior study, we modeled that individuals with hybrid immunity maintain antibody levels above a 75% correlate of immunity for 283 days after an immune-boosting event. These data offer insights into SARS-CoV-2 antibody decay kinetics that may inform COVID-19 vaccine timing in the younger (age under 60), healthy adult population.
No takes yet. Share an insight, caveat, or question.
Roe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: